All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Acute graft-versus-host disease (aGvHD) is a multisystem disorder that is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a reaction between donor immune cells and host tissues. Recent studies have identified a number of tissue-specific proteins as potential predictive biomarkers that could improve early and accurate diagnosis of the condition. The role of a lead biomarker candidate, elafin, in skin GvHD was investigated by Laura Solán from Hospital General Universitario Gregorio Marañón, Madrid, Spain et al.
On behalf of colleagues, Laura Solán reported results from their retrospective study at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal.
Solán et al. analyzed 110 consecutive patients (median age = 46 [range, 16–66]) who underwent haploidentical HSCT with post-transplant cyclophosphamide on Days 3 and 4, using MMF and CsA as GvHD prophylaxis between 2009 and 2016. In total, 23 cases were excluded; nine due to early death before Day 30, and 14 due to lack of plasma sample.
Plasma elafin levels after haplo-HSCT on Day 15 significantly correlated with the incidence of grade III-IV skin aGVHD. There was no association found between elafin levels at Day 15 and 30 and other organ-involvement of GvHD. Hence, the study authors found that elafin seemed to be a good predictive marker in skin aGVHD, therefore, to optimize treatment in these patients. Prospective trials are required to confirm these findings.
References